Baas Jørgen
Orthopaedic Research Laboratory, Dept. of Orthopaedics, Aarhus University Hospital, Denmark.
Acta Orthop Suppl. 2008 Aug;79(330):1-43.
Revision arthroplasty is a challenging aspect of the otherwise quite successful area of joint replacement surgery. The instable interaction between implant and host bone has often initiated a destructive process of inflammation and osteolysis, rendering the revision site sclerotic and with insufficient bone stock. One way of dealing with this is to build up a bed of tightly packed morselized bone graft to support the revision implant in a procedure often referred to as impaction grafting. Fresh frozen morselized femoral head allograft is the gold standard material for impaction grafting of the large defects usually involved in revision arthroplasty. The clinical outcome does not match that of primary arthroplasties. Implant subsidence is greater, implant survival shorter, and the bone graft is often not incorporated into living bone. The studies constituting this thesis have investigated ways of improving early implant fixation and bone graft incorporation. All studies used the same experimental canine model of early fixation and osseointegration of uncemented implant components inserted into a bed of impacted bone graft. Study I compared bone grafted implants where the morselized allograft was used alone or had been added rhBMP-2, the bisphosphonate pamidronate or a combination of the two. The main object was to see wether the previously observed growth factor related accelerated allograft resorption could be counteracted by the addition of an anti-catabolic drug. The study also compared HA-coated and non-coated porous Ti implants. The untreated control implants had better mechanical fixation than all other treatment groups. RhBMP-2 raised the total metabolic turnover of bone within the allograft with a net negative result on implant fixation. Pamidronate virtually blocked bone metabolism, also when combined with rhBMP-2. The HA-coated implants had more than twice as good mechanical fixation and improved osseointegration compared to the corresponding Ti implants. Study II investigated the addition of a bovine bone matrix lyophilisate (Colloss) to the allograft in three different doses. The main object was to see, whether the addition of a biological delivery device of low-dose osteogenic growth factors could provide a sufficient signal to increase the bioactivity of the bone graft without also yielding mechanical instability through increased allograft resorption. Allograft resorption increased with increased signal dose, but not to the extent that it affected implant fixation negatively at the observational time point. Mechanical implant fixation was doubled, and implant osseointegration and graft incorporation were improved. Study III compared a beta-TCP ceramic bone graft substitute (Ossaplast) with and without an osteogenic signal (Colloss E) to morselized allograft with and without the same signal. The object was to investigate, whether the addition of an osteogenic stimulus to a bio ceramic could replace biological allograft bone. The addition of an osteogenic signal improved early osseointegration of implants grafted with beta-TCP granules and increased their mechanical implant fixation to a level comparable to the allografted implants. All studies I-III confirmed that the topical addition of an osteogenic signal could increase implant osseointegration and the formation of new bone within a grafted defect. Another striking observation was the near-complete absence of fibrous tissue in the treated groups. The osseointegration of ceramic bone grafts improves when both the osteoconductive as well as the osteogenic components of bone are substituted. The effect on implant fixation of devices and pharmaceuticals that influence bone metabolism can be difficult to predict, as shown in study I. There seems to be a therapeutic window for these substances. This must be further explored prior to clinical use, as the adverse effects of overdosing bone anabolic and anti-catabolic substances can be detrimental.
翻修关节成形术是关节置换手术这一原本颇为成功的领域中具有挑战性的一个方面。植入物与宿主骨之间不稳定的相互作用常常引发炎症和骨溶解的破坏性过程,使翻修部位硬化且骨量不足。处理这一问题的一种方法是构建一层紧密压实的碎骨移植床,以在一种通常称为冲击植骨的手术中支撑翻修植入物。新鲜冷冻的股骨头碎骨同种异体移植物是用于翻修关节成形术通常涉及的大骨缺损冲击植骨的金标准材料。其临床结果与初次关节成形术不匹配。植入物下沉更明显,植入物存活时间更短,且骨移植通常不能与活骨融合。构成本论文的研究探讨了改善早期植入物固定和骨移植融合的方法。所有研究都使用了相同的实验犬模型,用于研究未骨水泥固定的植入物组件在冲击骨移植床中的早期固定和骨整合情况。研究I比较了使用单独的碎骨同种异体移植物或添加了重组人骨形态发生蛋白-2(rhBMP-2)、双膦酸盐帕米膦酸或两者组合的骨移植植入物。主要目的是观察添加一种抗分解代谢药物是否可以抵消先前观察到的与生长因子相关的同种异体移植物加速吸收现象。该研究还比较了羟基磷灰石涂层和未涂层的多孔钛植入物。未处理的对照植入物比所有其他治疗组具有更好的机械固定效果。rhBMP-2提高了同种异体移植物内骨的总代谢周转率,但对植入物固定产生了净负面结果。帕米膦酸实际上阻断了骨代谢,与rhBMP-2联合使用时也是如此。与相应的钛植入物相比,羟基磷灰石涂层植入物的机械固定效果提高了两倍多,且骨整合得到改善。研究II研究了以三种不同剂量向同种异体移植物中添加牛骨基质冻干物(Colloss)的情况。主要目的是观察添加一种低剂量成骨生长因子的生物递送装置是否能提供足够的信号来增加骨移植的生物活性,同时又不会因同种异体移植物吸收增加而产生机械不稳定。同种异体移植物吸收随信号剂量增加而增加,但在观察时间点并未达到对植入物固定产生负面影响的程度。植入物的机械固定效果提高了一倍,植入物骨整合和移植融合得到改善。研究III比较了添加和成骨信号(Colloss E)的β-磷酸三钙陶瓷骨移植替代物(Ossaplast)与添加和未添加相同信号的碎骨同种异体移植物。目的是研究向生物陶瓷中添加成骨刺激物是否可以替代生物同种异体骨。添加成骨信号改善了用β-磷酸三钙颗粒移植的植入物的早期骨整合,并将其机械植入物固定提高到与同种异体移植植入物相当的水平。所有研究I - III均证实,局部添加成骨信号可增加植入物骨整合以及移植缺损内新骨的形成。另一个显著观察结果是治疗组中几乎完全没有纤维组织。当骨的骨传导和成骨成分都被替代时,陶瓷骨移植的骨整合得到改善。如研究I所示,影响骨代谢的装置和药物对植入物固定的影响可能难以预测。这些物质似乎存在一个治疗窗口。在临床使用之前必须进一步探索这一点,因为过量使用骨合成代谢和抗分解代谢物质的不良影响可能是有害的。